Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers

[1] Lipton RB(2007)Migraine prevalence, disease burden, and the need for preventive therapy Neurology 68 343-349

[2] Bigal ME(2017)Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet 390 1211-1259

[3] Diamond M(2008)Direct cost burden among insured US employees with migraine Headache 48 553-563

[4] Hawkins K(2007)Indirect cost burden of migraine in the United States J Occup Environ Med 49 368-374

[5] Wang S(2009)The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis Value Health 12 55-64

[6] Rupnow M(1999)Burden of migraine in the United States: disability and economic costs Arch Intern Med 159 813-818

[7] Hawkins K(2018)The American Headache Society position statement on integrating new migraine treatments into clinical practice Headache 59 1-18

[8] Wang S(2018)ARISE: a phase 3 randomized trial of erenumab for episodic migraine Cephalalgia 38 1026-1037

[9] Rupnow MF(2018)Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study Lancet 392 2280-2287

[10] Hazard E(2017)Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol 16 425-434

[1] Lipton RB(2007)Migraine prevalence, disease burden, and the need for preventive therapy Neurology 68 343-349

[2] Bigal ME(2017)Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet 390 1211-1259

[3] Diamond M(2008)Direct cost burden among insured US employees with migraine Headache 48 553-563

[4] Hawkins K(2007)Indirect cost burden of migraine in the United States J Occup Environ Med 49 368-374

[5] Wang S(2009)The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis Value Health 12 55-64

[6] Rupnow M(1999)Burden of migraine in the United States: disability and economic costs Arch Intern Med 159 813-818

[7] Hawkins K(2018)The American Headache Society position statement on integrating new migraine treatments into clinical practice Headache 59 1-18

[8] Wang S(2018)ARISE: a phase 3 randomized trial of erenumab for episodic migraine Cephalalgia 38 1026-1037

[9] Rupnow MF(2018)Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study Lancet 392 2280-2287

[10] Hazard E(2017)Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol 16 425-434